QED Therapeutics
QED Therapeutics is a biotechnology company focused on precision medicine for FGFR-driven disorders.
Business Model:
Revenue: $0
Employees: 11-50
Rankings
Industries / Tags:
Detailed QED Therapeutics Information
Geographic Data
Address: 8000 Marina Blvd
City: Brisbane
State: CA
Zip: 94005
Country: US
Financial Info
Stage:
series unknown
Raised Last:
$65M
Raised Total:$65M
Social
Metrics
9,169,203Website Global Rank
196Website Monthly Traffic
Twitter Followers
Description
QED Therapeutics, a subsidiary of BridgeBio Pharma, is a biotechnology company focused on precision medicine for FGFR-driven disorders. Their lead candidate is infigratinib, a best-in-class FGFR kinase inhibitor that has shown meaningful clinical activity in chemotherapy-refractory cholangiocarcinoma with FGFR2 fusions. QED is also evaluating infigratinib in preclinical studies for the treatment of achondroplasia. They plan to develop infigratinib in additional FGFR-driven tumor types and rare disorders.
Contact Phone:
+18772805655
Contact Email:
| Announced Date | Company | Transaction | Money Raised |
|---|
| Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 1/2018 | Venture Round | $0 |
BridgeBio Pharma BridgeBio Pharma |
1/2018 | Venture Round | 1 | $65M |
BridgeBio Pharma BridgeBio Pharma |
|---|
| Announced Date | Name | Price |
|---|
Employee Departments
Employee States
|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|
